Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam
Clinical trial NCT05386680 · COMPLETED
Trial details
- NCT number
- NCT05386680
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-12
- Primary completion
- 2024-11-29
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.